Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,797 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Type 1 Diabetes Clear all
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

NCT01673178
View directory record Official record
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 13, 2026, 10:34 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

T and B Cell Responses in Autoimmune Diseases

NCT01947036
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2

NCT00592332
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, control group
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

NCT02673138
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
canagliflozin, basal interruption without canagliflozin
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051
View directory record Official record
Conditions
Diabetic Foot
Interventions
GAM501, Placebo, Standard of care
Biological · Other
Lead sponsor
Tissue Repair Company
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
29
States / cities
Montgomery, Alabama • Mesa, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

NCT05422053
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
t:slim X2 insulin pump with Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Idaho Falls, Idaho • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Results available

Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females

NCT01301456
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases
Interventions
Placebo, PF-04856883
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Chula Vista, California • Miami, Florida • Miramar, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 13, 2026, 10:34 PM EDT
Recruiting Not applicable Interventional

Type 1 Diabetes Adolescents for Healthier Lifestyles Study

NCT06878872
View directory record Official record
Conditions
Type 1 Diabetes, Eating Behavior, Adolescent Obesity
Interventions
T1DAL Program
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 13, 2026, 10:34 PM EDT
Completed No phase listed Observational

Green Digital Diabetes Waste Project

NCT06071325
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 120 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Burlingame, California • Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 13, 2026, 10:34 PM EDT
Completed No phase listed Observational

Ability to Cope With Type 1 Diabetes

NCT00206362
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 13, 2026, 10:34 PM EDT
Recruiting Not applicable Interventional

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

NCT01999361
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Myfortic
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 13, 2026, 10:34 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

NCT07160257
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 13, 2026, 10:34 PM EDT
Recruiting Not applicable Interventional

Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes

NCT06967701
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Latent Autoimmune Diabetes in Adult (LADA), Pancreatitis
Interventions
Exercise program, Self-monitoring
Behavioral
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Results available

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT05158244
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-07081532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus

NCT01781975
View directory record Official record
Conditions
Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
Interventions
Imatinib Mesylate, Placebo (For imatinib mesylate)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 3 Interventional

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

NCT02638805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
ITCA 650 Osmotic Mini Pump 20/60 mcg/day, ITCA 650 Osmotic Mini Pump 60 mcg/day, Metformin, Liraglutide
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 13, 2026, 10:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls

NCT01592539
View directory record Official record
Conditions
Type 1 Diabetes,, Bone
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Not applicable Interventional

Exercise Physiology Study

NCT03090451
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Trial Testing the Bionic Pancreas With ZP4207

NCT02971228
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
Drug · Device
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

NCT05731544
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
BMF-219
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
443 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
36
States / cities
Canoga Park, California • Fountain Valley, California • La Mesa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 13, 2026, 10:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetics of Muscle Insulin Resistance

NCT03259984
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00027287
View directory record Official record
Conditions
Diabetes Mellitus, Macular Edema
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

NCT01794364
View directory record Official record
Conditions
Healthy
Interventions
PF-06291874, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 13, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Type 1 Diabetes Data Acquisition and Transfer Adherence Study

NCT03228004
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glooko MeterSync
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 13, 2026, 10:34 PM EDT